Novo Nordisk’s blockbuster weight loss drug Ozempic and Wegovy is set to go generic, opening the door for cheaper competing versions. This change will significantly lower the price of a costly medicine that had been largely unaffordable to nearly all but the wealthiest people in countries such as India, China, Canada, Brazil, Turkey, and South Africa.
The expiration of patent protection in these nations means that numerous generic manufacturers are racing to produce supplies and win regulatory approvals. Huge demand is expected from patients who could not afford Novo Nordisk’s offering but can budget for cheaper generics. With prices predicted to drop to around $15 a month, this will make the medication more accessible to millions of people worldwide.
In countries such as India and China, where over 800 million adults are obese or overweight and 360 million have diabetes, generic versions of Ozempic and Wegovy will be particularly beneficial. The introduction of these generics has sparked excitement among manufacturers and patients alike, with some expecting a “game-changing” impact on the treatment of obesity.
As Novo Nordisk faces increased competition, its stock has plummeted due to the erosion of its market share. However, the company is working to preserve its monopoly by positioning its original version as a premium brand in certain markets.
The generic versions are expected to be available soon in India and China, with the first generics arriving this weekend. In Canada, where Novo Nordisk’s patent protection expired in January, some U.S. patients may seek to import the drug from Canadian pharmacies. Chinese manufacturers have already been producing active ingredients for semaglutide sold globally, including compounded versions for American consumers.
The delay in generic competition has significant implications, with millions of Americans potentially missing out on access to this life-saving medication. Spending on Novo Nordisk’s version is estimated to be inflated by tens of billions of dollars, highlighting the importance of making high-priced medications more accessible to those who need them.
Source: https://www.nytimes.com/2026/03/19/health/ozempic-wegovy-generic-india-china-canada.html